Fulvestrant in heavily pretreated ER-positive postmenopausal metastatic breast cancer patients: A phase II study

1144 Background: Fulvestrant (F), an estrogen receptor down-regolator drug, has been demonstrated to be effective in ER +ve postmenopausal metastatic breast cancer (MBC) progressing on tamoxifen (Howell A., 1995) and phase III trials have shown that response rates, TTP e OS are comparable to those obtained with anastrozole (Howell A., 2000 and Mauriac L., 2003). Methods: The aim of the study was to evaluate efficacy and toxicity of F in ER+ve post-menopausal metastatic breast cancer patients (MBC pts) heavily pre-treated both with hormonal agents and chemotherapy. From 5/2006 to 10/2007 22 pts. in this setting, were treated with F 250 mg i.m. q 28 days. Results: All pts, median age 63 (range 39–81), had received prior anthracycline and taxane-based chemotherapy and had been treated with a median of 2 chemotherapy regimens (range 1–5), and a median of 3 hormonal agents (range 1–4). Sites of MBC were: 13 bone, 2 liver, 4 lung, 1 CNS, 5 nodes, 3 skin, 4 breast. The 22 pts received a total of 117 cycles of F:...